Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

Published Date: 03 Jun 2025

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data ...

Read Full News

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

Could occupational exposure to sawdust explain this case?

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

— News, features, and commentary about cancer-related issues

Benign or Malignant? No Way to Tell Radiologically

Case shows importance of accurate preop diagnosis

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Todays Updates

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Latest News

Could occupational exposure to sawdust explain this case?

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

— News, features, and commentary about cancer-related issues

Case shows importance of accurate preop diagnosis

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

News, features, and commentary about cancer-related issues

More Evidence Ties Microplastics to Lung Cancer

Observational study shows greater microplastic burden in patients with lung malignancy

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

Health news and commentary gathered by MedPage Today staff

9/11's Latest Wave of Cancers, 25 Years On

The health ramifications of the attack persist

Study Warns on Venetoclax in Double-Hit Lymphoma

Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

News, features, and commentary about cancer-related issues

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Non-significant 4-month PFS increase with sacituzumab govitecan-pembrolizumab, no OS benefit

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

Death risk cut by 54% with B7-H3-targeting tambotatug pelitecan and risvutatug rezetecan

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Overall survival favored nivolumab-ipilimumab alone in LONESTAR trial

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

All responding NCCN members reported shortages, priorities identified but solutions still needed

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Omitting prophylactic cranial irradiation led to improved cognitive failure-free survival

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Health news and commentary gathered by MedPage Today staff

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Early efficacy among the highest seen in lung cancer, expert says

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

Bispecific antibody and ADC together impress in early study

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS trend

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

If approved, immunotherapy gotistobart could offer a chemo-free option in second-line setting

Recommended News For You

The response of bipolar patients to lithium may be predicted by ancestry.

Report suggests a big improvement in lung cancer survival

Rectal Cancer 'Crisis'; Smells Like Cancer; Flushing Away Clues to Colon Cancer

For Localized Prostate Cancer, HIFU Is Not Worse Than Prostatectomy.

Emerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage

After two years, a significant left nasal obstruction was finally diagnosed.

Recommended Articles For You

Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection? 

Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders 

The Mystery of Carotid Body Tumors: The Facts You Need to Know 

Tumor Ecosystem Activity Biomarkers in Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An individual state lost $4.02 billion due to untreated mental illness.

2.

Antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer

3.

Black Canadians Face Multiple Barriers to Blood Donation

4.

Study: Discovery of cellular identity may influence cancer treatment

5.

Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer

1.

Drug Safety Through Oncology Survivorship Medication Monitoring Frameworks

2.

Digital Oncology Navigation Systems for Coordinated Multidisciplinary Cancer Care

3.

Simulation for Hematology Emergencies: Enhancing Clinical Preparedness and Patient Outcomes

4.

Colon Cancer Staging: What You Need to Know

5.

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

1.

International Conference on Oncology, Cardiology and Critical Care Policy

2.

International Conference on Innovations in Critical Care for Oncology and Cardiology

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Cancer Nursing and Hematology Support

1.

How Multidisciplinary Teams Support Modern Cancer Care

2.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

3.

Navigating the Complexities of Ph Negative ALL - Part II

4.

Navigating the Complexities of Ph Negative ALL - Part VIII

5.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot